Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
MetroCity Bankshares, Inc. reported a net income of $24.3 million for the third quarter of 2026, up from $17.3 million in the same period of 2025. The company saw significant growth in net interest income, which rose to $43.6 million for the quarter, while total assets decreased slightly to $4.60 billion from $4.77 billion at year-end 2025.
For the nine months ended September 27, 2026, Wendy's reported total revenues of $1.66 billion, a slight increase from $1.63 billion in the prior year, though net income decreased significantly to $70.4 million from $138.6 million. The decline in profitability was driven by higher cost of sales, increased general and administrative expenses, and a reduction in franchise royalty revenue.
Hyster-Yale, Inc. reported its third quarter 2026 financial results, showing a consolidated revenue of $827.4 million, a 15.5% decrease compared to the prior year. The company recorded a net loss attributable to stockholders of $14.9 million for the quarter, an improvement from the $31.6 million loss in Q2 2026 but down from a $2.3 million loss in Q3 2025.
CorVel Corporation reported a 11.5% increase in quarterly revenue to $267.1 million and a 22.1% increase in net income to $34.1 million for the period ended September 30, 2026. For the first six months of the fiscal year, net income rose to $66.3 million compared to $55.1 million in the prior year, driven by strong gross profit growth.
PJT Partners reported total revenues of $1.29 billion for the nine months ended September 30, 2026, an increase from $1.18 billion in the prior year period. Net income before taxes rose to $251.3 million for the nine-month period, despite an increase in total expenses driven primarily by higher compensation and benefits costs.
Aclaris Therapeutics reported a net loss of $59.8 million for the nine months ended September 30, 2026, compared to $45.1 million for the same period in 2025. The company significantly increased its cash position through at-the-market sales of common stock, raising approximately $116.2 million in net proceeds during the first nine months of 2026.
Agenus Inc. reported its financial results for the quarter ended September 30, 2026, highlighting continued investment in its clinical-stage immunotherapy pipeline and strategic collaborations. The filing reflects the company's focus on managing operational costs while advancing lead candidates toward key regulatory and clinical milestones.
Mettler Toledo International Inc/ Financial Results
Mettler-Toledo reported third quarter 2026 results with reported sales increasing 6% to $1.094 billion, driven by 16% growth in Asia/Rest of World. GAAP EPS rose to $12.29 from $10.57 in the prior year, while Adjusted EPS grew 13% to $12.57. The company raised its full-year 2026 Adjusted EPS guidance to a range of $47.70 to $47.90.
Term
Q3 2026
“We delivered an excellent third quarter, achieving relatively broad-based growth across our portfolio while capitalizing on improving market demand. Performance was particularly strong in Asia / Rest of World. Improved sales volume and strong execution of our strategic initiatives resulted in another quarter of robust growth in Adjusted EPS.”
Patrick Kaltenbach, President and Chief Executive Officer
Kayne Anderson BDC reported Q3 2026 net investment income of $30.2 million ($0.46 per share), which exceeded its base dividend. The company also declared a Q4 2026 dividend of $0.40 per share and noted a slight decline in NAV per share to $15.71 due to realized and unrealized losses.
Term
Q3 2026
“Third quarter net investment income of $0.46 per share exceeded our $0.40 base dividend and generated an annualized ROE from net investment income of 11.7%.”
Doug Goodwillie, Co-Chief Executive Officer
“With the declaration of our fourth quarter dividend, we delivered on our commitment to pay the $0.40 base dividend throughout 2026 and we ended the quarter with $0.32 per share of undistributed net investment income.”
Magnachip Semiconductor Corp reported its third-quarter 2026 results, highlighting steady demand in its Power Solutions segment despite seasonal fluctuations in Display. The company maintained a strong cash position and focused on operational efficiencies to offset rising manufacturing costs.
Blueport Acquisition Ltd reported a net income of $534,862 for the nine months ended September 30, 2026, primarily driven by $1,560,917 in interest earned on investments held in the Trust Account. The company is a blank check entity that has not yet commenced operations and is currently seeking a business combination, with $59,345,372 held in its Trust Account as of the period end.
Orion Properties Inc. reported a net income of $7.7 million for the nine months ended September 30, 2026, a significant recovery from a net loss of $103.5 million in the prior year period, primarily driven by a $28.8 million gain on real estate dispositions and lower impairment charges. Total revenues decreased slightly to $106.0 million for the nine-month period, while total assets stood at $1.14 billion as of September 30, 2026.
Kura Sushi USA faces risks related to long-term non-cancelable leases, labor shortages, and potential negative publicity from social media or employee claims. The company relies on public offerings and cash flows for capital, noting recent stock offerings in fiscal years 2021, 2023, and 2025 to fund its expansion.
Aclarion, Inc. reported a net loss of $8.2 million for the nine months ended September 30, 2026, compared to a $5.3 million loss in the prior year period. While net revenue grew to $80,081, operating expenses increased significantly, particularly in general and administrative costs, though the company strengthened its cash position to $14.2 million through financing activities.
Sphere Entertainment Co. reported revenues of $274.3 million for the quarter ended September 30, 2026, but saw its net loss widen to $176.0 million compared to $125.7 million in the prior year period. The increased loss was primarily driven by $177.6 million in impairment charges and higher operating expenses.
Hyster-Yale reported Q3 2026 financial results with revenue of $827.4 million and a net loss of $14.9 million. While revenue declined 15% year-over-year due to unfavorable product mix, bookings increased 45% to $550 million, signaling a recovery from the 2025 cyclical low. The company launched new cost-reduction initiatives targeting $100 million in savings at maturity.
8x8, Inc. reported total revenue of $192.0 million for the quarter ended September 30, 2026, representing growth from $184.1 million in the prior year period. The company achieved a net income of $3.39 million for the quarter, a significant improvement compared to $0.77 million in the same period last year, driven by higher service revenue and reduced sales and marketing expenses.
Apollo Debt Solutions BDC reported total investment income of $1.76 billion for the nine months ended September 30, 2026, compared to $1.35 billion in the prior year period. Net assets decreased to $13.51 billion from $14.77 billion at year-end 2025, primarily driven by $1.87 billion in net capital share repurchases and $971 million in distributions to shareholders.
This filing details a Voting Agreement between KrimGP2010, LLC and North Street Properties, LLC regarding their membership interests in NGL Energy Holdings LLC, the general partner of NGL Energy Partners LP. The agreement requires North Street to vote its 57,992.79 units as directed by KrimGP, specifically to maintain the current Board composition and support KrimGP's nominees, while granting an irrevocable proxy to H. Michael Krimbill.
Horizon Technology Finance Corp reported a net decrease in net assets resulting from operations of $28.2 million for the quarter ended September 30, 2026, driven by significant net unrealized depreciation on investments. Total investment income decreased to $24.1 million compared to $26.3 million in the prior year period, while net asset value per share declined to $5.56 from $6.98 at year-end 2025.
eGain Corp reported Q1 fiscal 2027 results with revenue of $21.9 million and non-GAAP EPS of $0.09, both exceeding the high end of company guidance. The company highlighted 11% year-over-year growth in AI customer annual recurring revenue (ARR) and repurchased $3.6 million of its common stock during the quarter.
Term
Q1 2027
“Being named a Leader in Gartner’s inaugural Magic Quadrant™ for Customer Service Knowledge Management Systems, with the highest product score for the Compliance-Driven Service Center use case in the companion Critical Capabilities report, is raising our visibility with enterprise buyers. As AI moves into production, enterprises need trusted, governed knowledge to deliver accurate answers and measurable results, a point our customers made clearly at Solve26. We’re focused on converting this interest into new customers and expansions.”
Monster Beverage Corporation reported third quarter 2026 net sales of $2.56 billion, a 16.7% increase year-over-year, driven by strong performance in the Monster Energy Drinks segment. Net income per diluted share rose 7.8% to $0.29, while international sales grew 28.1% to represent 47% of total revenue.
Mercer International reported third quarter 2026 results, showing an improved Operating EBITDA of negative $2.9 million compared to negative $28.1 million in the prior year period. The company highlighted a major balance sheet restructuring agreement to address $1.275 billion in senior notes and raise $400 million in new capital. The 'One Goal One Hundred' cost-savings program remains on track, achieving $22 million in savings during the quarter.
Term
Q3 2026
“As announced on November 2, 2026, we entered into restructuring support agreements with holders of more than 87% of the aggregate outstanding principal amount of our senior notes and with holders of a majority of the outstanding shares of our common stock that provide for a comprehensive recapitalization of the company (the "Recapitalization"). The transaction provides for, among other things, the exchange of approximately $1.1 billion of existing senior notes for equity, eliminates approximately $96 million of annual cash interest on our senior notes and provides for $400 million of new capital through a fully-backstopped rights offering of senior secured notes.”
Valhi, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $84.1 million compared to $8.4 million in the prior year, driven by a 10.9% increase in net sales. The company's total assets stood at $2.58 billion, and it maintained a steady quarterly dividend of $0.08 per share.
Tectonic Therapeutic reported Q3 2026 financial results, ending the period with $234.7 million in cash which is expected to fund operations into Q1 2029. The company highlighted clinical progress, including favorable Phase 1a results for TX2100 and the dosing of the first patient in the Phase 2a ALPINE trial for TX45. Topline results for the APEX Phase 2 trial in PH-HFpEF are anticipated by the end of January 2027.
Term
Q3 2026
“The favorable safety, tolerability and PK results from the single ascending-dose portion of our TX2100 Phase 1a trial in healthy adult volunteers, together with FDA Fast Track designation for HHT and IND clearance for our Phase 1b trial, support our plans to evaluate TX2100 in patients with HHT.”
Alise Reicin, M.D., President and Chief Executive Officer
“We plan to initiate an open-label Phase 1b trial in patients with hematologic-support-dependent HHT by year-end 2026 and, in parallel, a placebo-controlled Phase 2 trial in patients with moderate-to-severe HHT in early 2027. We are also approaching a critical milestone for TX45, with topline results from our APEX Phase 2 trial in PH-HFpEF anticipated by the end of January 2027.”
Alise Reicin, M.D., President and Chief Executive Officer
Cryoport reported Q3 2026 revenue of $50.2 million, a 14% increase year-over-year, driven by 20% growth in commercial Cell and Gene Therapy revenue. The company achieved positive adjusted EBITDA of $1.1 million and raised its full-year 2026 revenue guidance to a range of $197 million to $199 million.
Term
Q3 2026
“Cryoport delivered third quarter revenue of $50.2 million, reflecting continued momentum across our core cell and gene therapy (CGT) business. Revenue from commercial CGT clients increased 20% year over year, BioStorage/BioServices revenue expanded 25%, and total Life Sciences Services revenue grew 18%, underscoring the strength of our integrated platform and the growing demand for our solutions.”
Jerrell Shelton, CEO of Cryoport
“Our strong year-to-date performance, combined with expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and continued demand for MVE’s industry-leading products, gives us confidence in our outlook. As a result, we are increasing our full-year 2026 revenue guidance to a range of $197 million to $199 million.”
Bimini Capital Management reported Q3 2026 net income of $1.0 million, or $0.10 per share, down from $1.8 million in the prior year period. Book value per share increased to $1.47 as of September 30, 2026, while the company highlighted the benefits of its strategic pivot toward a more diversified asset management model despite severe fixed-income market duress.
Term
Q3 2026
“The Company’s results for the quarter demonstrate the benefits of our recent pivot to a more diversified asset manager with less reliance on the levered RMBS strategy. The fixed income markets broadly, and the Agency RMBS market more specifically, generated poor results for the quarter, and the equity and investment grade credit markets were negatively impacted by the poor performance of AI/hyperscalers. Despite these pressures, Bimini was able to generate positive results for the quarter and believes it remains well positioned to continue to do so even while market conditions remain challenging.”
Robert E. Cauley, Chairman and Chief Executive Officer
For the three months ended September 30, 2026, Brilliant Earth Group, Inc. reported net sales of $112.8 million and returned to profitability with a net income of $2.4 million compared to a net loss in the prior year period. However, for the nine-month period, the company recorded a net loss of $5.2 million, reflecting ongoing challenges despite a 4.6% year-over-year increase in nine-month net sales.
Warby Parker Inc. reported its third-quarter results for 2026, showing continued revenue growth driven by retail store expansions and increased active customer counts. The company highlighted improvements in gross margin and adjusted EBITDA, while maintaining its full-year outlook for sustainable growth and profitability.
Gyre Therapeutics reported Q3 2026 revenue of $32.9 million and affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million. The company is preparing for a potential China NMPA decision on its liver fibrosis candidate F351 by early 2027 and is advancing several protein degrader programs into clinical trials.
Term
Q3 2026
“I am pleased with our execution in the third quarter, our first full quarter incorporating Cullgen's operations within Gyre Therapeutics. We are advancing our protein degrader pipeline toward first-in-human data and initiating new clinical programs next year. Meanwhile, after recently completing an onsite inspection by China’s National Medical Products Administration, or NMPA, we continue to prepare for the China NMPA decision on F351 for CHB-induced liver fibrosis, which we anticipate launching, if approved, sometime in the first half of 2027. Together, these programs are expected to drive our next phase of growth and demonstrate the strength of our unique business model, combining U.S. innovation with capital-efficient operations in China.”
Dr. Ying Luo, President and Chief Executive Officer